A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice

Blood Cancer Journal

Volumn 3, Issue 11, 2013, Pages

  Hu, Y ^a   Zheng, M ^b   Gali, R ^a   Tian, Z ^a   Görgün, G Topal ^a   Munshi, N C ^a   Mitsiades, C S ^a   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BALB c mouse; CMYC; KRAS12V; Multiple myeloma (MM); Plasmacytoma; Retroviral transduction and transplantation

Indexed keywords

IMMUNOGLOBULIN M; INTERLEUKIN 3; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROTEIN BCL 6; PROTEIN KRAS12V; STAT3 PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GENE DEREGULATION; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PENETRANCE; PLASMA CELL; PLASMACYTOMA; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY;

EID: 84888413607     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.53     Document Type: Article

References (49)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187. (Pubitemid 37328787)
3. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338. (Pubitemid 46218843)
4. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96: 1505-1511. (Pubitemid 30658483)
5. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-5622.
6. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
7. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 1969; 222: 994-995.
8. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90: 754-765. (Pubitemid 27299116)
9. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004; 104: 2149-2154. (Pubitemid 39297870)
10. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007; 6: 1701-1708. (Pubitemid 46954046)
11. Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012; 7: e51892.
12. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-180. (Pubitemid 351163163)
13. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007; 11: 349-360. (Pubitemid 46518314)
14. Morito N, Yoh K, Maeda A, Nakano T, Fujita A, Kusakabe M et al. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res 2011; 71: 339-348.
15. Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004; 113: 1763-1773. (Pubitemid 39071668)
16. Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011; 145: 145-158.
17. Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA 2000; 97: 1760-1765. (Pubitemid 30118516)
18. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
19. Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 2002; 21: 1922-1927. (Pubitemid 34259195)
20. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18.
21. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of E mu-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol 1989; 9: 67-73. (Pubitemid 19024779)
22. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptorassociated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007; 27: 253-267. (Pubitemid 47284931)
23. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008; 20: 67-82.
24. Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse 3rd HC, Taddesse-Heath L et al. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 2001; 21: 310-318.
25. Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S. BCL2 accelerates inflammation- induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Res 2003; 63: 8656-8663. (Pubitemid 38064040)
26. Kobayashi H, Potter M, Dunn TB. Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice. J Natl Cancer Inst 1962; 28: 649-677.
27. Potter M, Fahey JL, Pilgrim HI. Abnormal serum protein and bone destruction in transmissible mouse plasma cell neoplasm (multiple myeloma). Exp Biol Med 1957; 94: 327-333.
28. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006; 17: 2533-2545. (Pubitemid 44300969)
29. Underhill GH, George D, Bremer EG, Kansas GS. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 2003; 101: 4013-4021. (Pubitemid 36857880)
30. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62. (Pubitemid 34874618)
31. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol 2000; 1: 526-532.
32. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997; 276: 596-599. (Pubitemid 27193684)
33. Schlosser I, Holzel M, Hoffmann R, Burtscher H, Kohlhuber F, Schuhmacher M et al. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 2005; 24: 520-524. (Pubitemid 40188599)
34. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 2001; 29: 397-406. (Pubitemid 32060926)
35. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4: R69.
36. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385: 544-548. (Pubitemid 27074674)
37. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
38. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601. (Pubitemid 38796850)
39. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
40. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16: 245-256. (Pubitemid 34075816)
41. Eguchi T, Takaki T, Itadani H, Kotani H. RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 2007; 26: 509-520. (Pubitemid 46160965)
42. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
43. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010; 38: 5718-5734.
44. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759-772.
45. Coffin JMHS, Varmus HE. Retrovirus. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1997.
46. Potter M, Wiener F. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 1992; 13: 1681-1697.
47. Kurie JM, Morse 3rd HC, Principato MA, Wax JS, Troppmair J, Rapp UR et al. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice. Oncogene 1990; 5: 577-582.
48. Seed TM, Chubb GT, Tolle DV. Sequential changes in bone marrow architecture during continuous low dose gamma irradiation. Scanning Microsc 1981; 4: 61-72. (Pubitemid 12049227)
49. Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci USA 1998; 95: 2429-2434.